These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1516458)

  • 1. The threat of resistance to the new oral cephalosporins.
    Cullmann W
    Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W; Dick W; Stieglitz M; Opferkuch W
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of beta-lactamase stability in treating today's respiratory tract infections.
    Cullmann W
    Respiration; 1993; 60 Suppl 1():10-5. PubMed ID: 8386847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
    Bedenić B; Singer S
    Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics.
    Neu HC; Chin NX
    Chemioterapia; 1985 Aug; 4(4):271-7. PubMed ID: 3876887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.
    Dworzack DL; Pugsley MP; Sanders CC; Horowitz EA
    Eur J Clin Microbiol; 1987 Aug; 6(4):456-9. PubMed ID: 3499316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative and quantitative aspects of beta-lactamase production as mechanisms of beta-lactam resistance in a survey of clinical isolates from faecal samples.
    Simpson IN; Knothe H; Plested SJ; Harper PB
    J Antimicrob Chemother; 1986 Jun; 17(6):725-37. PubMed ID: 3488308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
    Bedenic B; Vranes J; Suto S; Zagar Z
    Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins.
    Labia R; Morand A; Tiwari K; Sirot D; Chanal C
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():219-23. PubMed ID: 2808209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
    Gutkind GO; Di Conza J; Power P; Radice M
    Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.
    Sanders WE; Sanders CC
    Rev Infect Dis; 1988; 10(4):830-8. PubMed ID: 3055176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.